Role of miRNAs in vascular development

Sufianov, Albert; Begliarzade, Sema; Kudriashov, Valentin; Nafikova, R A; Ilyasova, Tatiana; Liang, Yanchao

doi:10.1016/j.ncrna.2022.09.010

Cited by 10 publications

(12 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…miR-126 is not only expressed in capillaries and larger vascular endothelial cells, but also highly expressed in highly vascularized tissues such as heart, liver and umbilical vein endothelial cells, and some studies have shown that it is expressed in progenitor cells, endothelial cells Lineage, expression in hematopoietic cell lines. [9,17,18] miR-126 is down-regulated in most of the cancers studied. Aberrant expression of miR-126 is associated with the lung, thyroid, breast, genital tracts, gastrointestinal tract, and some other cancers in the previous studies.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Differentially expressed miRNA may be used as the indicator of early diagnosis, molecular typing and prognosis, including ovarian cancer. [5][6][7] microRNA (miR-126), originally identified as an endothelial-specific miRNA playing an essential role in angiogenesis and vascular integrity, [8,9] it has been shown to function as a critical tumor suppressor in various types of solid tumors. [10][11][12][13] Overexpressed miR-126 can inhibit drug resistance cell proliferation and promote apoptosis of drug resistance cell, and invasion of cancer cells in various types of solid tumors.…”

Section: Introductionmentioning

confidence: 99%

“…Differentially expressed miRNA may be used as the indicator of early diagnosis, molecular typing and prognosis, including ovarian cancer. [5–7] microRNA (miR-126), originally identified as an endothelial-specific miRNA playing an essential role in angiogenesis and vascular integrity, [8,9] it has been shown to function as a critical tumor suppressor in various types of solid tumors. [10–13]…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer

et al. 2023

View full text Add to dashboard Cite

Background: Ovarian cancer is the leading cause of gynecological cancer related death in females worldwide. Our previous study demonstrated that decreased expression of microRNA (miR-126) promoted ovarian cancer angiogenesis and invasion by targeting VEGF-A. This study aimed to evaluate the clinical validity of miR-126 as a prognostic marker for epithelial ovarian cancer (EOC).Patient concerns: The patients with EOC ranged in age from 27 to 79 years, with a mean age of 57 years.Diagnosis: All patients had never had chemotherapy or biotherapy, and the diagnoses were confirmed pathologically in all cases Methods: MiR-126 levels in EOC tissue and normal ovaries were determined by qRT-PCR. Its prognostic value was analyzed using the Cox proportional hazards regression model. Survival curves were drawn using the Kaplan-Meier method.Results: In this study, we found that compared to normal tissues, miR-126 expression was lower in EOC tissues, particularly in omental metastases. Though in our previous study we found that miR-126 may inhibit proliferation and invasion in EOC cell lines, but in this study patients with elevated miR-126 expression exhibited poor overall survival and relapse free survival. Multivariate Cox regression analysis showed that miRNA-126 was an independent prognostic factor for poor relapse-free survival (P = .044). Receiver operating characteristic analysis showed that the area under the curve of miR-126 was 0.806 (95% confidence interval, 0.669-0.942). Conclusion:In this study, we established miR-126 as a potential independent biomarker for predicting recurrence in patients with EOC.Abbreviations: EOC = epithelial ovarian cancer, miR-126 = microRNA, OC = ovarian cancer, OS = overall survival, PFI = platinum-free interval, RFS = relapse-free survival, ROC = receiver operating characteristic.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…and the cytokines secreted by them. disorder [ [2] , [3] , [4] , [5] ]. Non-coding RNAs (ncRNAs) is a class of protein non-coding molecules that widely exist in eukaryotes, participate in a variety of biological regulation processes, and have been widely studied in human diseases [ [6] , [7] , [8] , [9] , [10] , [11] ].…”

Section: Introductionmentioning

confidence: 99%

Studies on the role of non-coding RNAs in controlling the activity of T cells in asthma

Sufianov

Bessonova

Begliarzade³

et al. 2023

Non-coding RNA Research

View full text Add to dashboard Cite

Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors

Kang,

Li,

Liu

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Vascular endothelial growth factor A (VEGF-A), a highly conserved dimeric glycoprotein, is a key regulatory gene and a marker molecule of angiogenesis. The upregulation of VEGF-A facilitates the process of tumor vascularization, thereby fostering the initiation and progression of malignant neoplasms. Many genes can adjust the angiogenesis of tumors by changing the expression of VEGF-A. In addition, VEGF-A also exhibits immune regulatory properties, which directly or indirectly suppresses the antitumor activity of immune cells. The emergence of VEGF-A-targeted therapy alone or in rational combinations has revolutionized the treatment of various cancers. This review discusses how diverse mechanisms in various tumors regulate VEGF-A expression to promote tumor angiogenesis and the role of VEGF-A in tumor immune microenvironment. The application of drugs targeting VEGF-A in tumor therapy is also summarized including antibody molecule drugs and traditional Chinese medicine.

show abstract

Role of miRNAs in vascular development

Cited by 10 publications

References 94 publications

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer

The clinical validity of miR-126 as a prognostic marker in epithelial ovarian cancer

Studies on the role of non-coding RNAs in controlling the activity of T cells in asthma

Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors

Contact Info

Product

Resources

About